Aclarion, Inc. · NASDAQ (us_market)
Healthcare · Health Information Services · United States
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-13$9.69 RISE2026-02-05$2.36 PEAK2026-04-22$3.73 191d | -75.6% 115d | Missed | Missed | — | — | +58.1% 76d | Missed |
DROP2025-10-13$9.69 RISE2025-11-19$5.87 PEAK2026-01-08$8.17 87d | -39.4% 37d | Missed | Missed | — | — | +39.2% 50d | Missed |
DROP2025-03-24$20.79 RISE2025-07-31$6.95 PEAK2025-10-13$9.69 203d | -66.6% 129d | Missed | Missed | — | — | +39.4% 74d | Missed |
DROP2025-01-24$497.48 RISE2025-06-03$6.45 PEAK2025-07-28$7.84 185d | -98.7% 130d | Missed | Missed | — | — | +21.6% 55d | Missed |
DROP2025-01-03$2,695.41 RISE2025-04-30$6.39 PEAK2025-07-28$7.84 206d | -99.8% 117d | Missed | Missed | — | — | +22.7% 89d | Missed |
DROP2024-07-23$2,948.67 RISE2024-10-15$1,519.56 PEAK2025-01-03$2,695.41 164d | -48.5% 84d | Missed | Missed | — | — | +77.4% 80d | Missed |
DROP2024-05-22$3,021.03 RISE2024-09-11$1,528.60 PEAK2024-10-22$2,080.35 153d | -49.4% 112d | Missed | Missed | — | — | +36.1% 41d | Missed |
DROP2024-02-12$17,185.50 RISE2024-06-21$2,550.69 PEAK2024-07-23$2,948.67 162d | -85.2% 130d | Missed | Missed | — | — | +15.6% 32d | Missed |
DROP2023-12-20$50,507.28 RISE2024-04-22$2,487.38 PEAK2024-04-25$3,554.69 127d | -95.1% 124d | Missed | Missed | — | — | +42.9% 3d | Missed |
DROP2023-04-24$185,241.59 RISE2023-05-26$85,384.80 PEAK2023-06-12$191,030.41 49d | -53.9% 32d | Missed | Missed | — | — | +123.7% 17d | Missed |
DROP2022-12-02$127,353.60 RISE2023-04-03$86,832.00 PEAK2023-06-12$191,030.41 192d | -31.8% 122d | Missed | Missed | — | — | +120.0% 70d | Missed |
DROP2022-09-12$196,819.20 RISE2022-12-27$56,440.80 PEAK2023-02-07$120,117.60 148d | -71.3% 106d | Missed | Missed | — | — | +112.8% 42d | Missed |
DROP2022-05-23$237,485.52 RISE2022-09-30$112,592.16 PEAK2022-10-31$154,850.41 161d | -52.6% 130d | Missed | Missed | — | — | +37.5% 31d | Missed |
DROP2022-04-22$393,638.41 RISE2022-06-21$117,802.08 PEAK2022-09-12$196,819.20 143d | -70.1% 60d | Missed | Missed | — | — | +67.1% 83d | Missed |
No scored news yet for a sentiment trend.
Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. Stock targets and ratings also updated.
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $7 to $7.5.
Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse takeoverStock price
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclarion (ACON) delivered earnings and revenue surprises of +13.55% and -29.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.55) by 13.55 percent. This is a 85.62 percent increase over losses of $(9.32) per share from the same
Natera (NTRA) delivered earnings and revenue surprises of -5.26% and +13.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volumeThe CLARITY randomized
“Matching the right procedure to the right patient is what moves the field forward” Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex...
BROOMFIELD, Colo., May 06, 2026 -- Aclarion, Inc., , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms through its...
Aclarion Inc:Aclarion announces second commercial agreement with Weill Cornell Medicine...
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through
Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflowsAdvancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated...
Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing...
Aclarion, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $2.5 million worth of its shares. The repurchases will be funded from existing cash and cash...
BROOMFIELD, Colo., April 22, 2026 -- Aclarion, Inc., , a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence algorithms through its...
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its
Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pending patents
Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross marginsExpands intellectual property portfolio to 64 issued and...
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 -- Aclarion, Inc., ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACON | -4.09% | +14.69% | -28.70% | -49.38% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -7.06% | +20.40% | -25.25% | -62.07% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-12 | Neal David K | Director | P Open-market purchase | 2,500 | $3.10 | +$7.8K |
| 2026-05-12 | Breidbart Scott | Director | P Open-market purchase | 5,664 | $3.18 | +$18.0K |
| 2026-05-11 | Ness Brent | Chief Executive Officer | P Open-market purchase | 6,289 | $3.18 | +$20.0K |
| 2026-05-08 | Wesemann William | Director | P Open-market purchase | 1,562 | $3.30 | +$5.2K |
| 2025-12-01 | Ness Brent | Chief Executive Officer | P Open-market purchase | 10 | $6.20 | +$62 |
| 2025-09-03 | Gould Gregory A | CFO | A Grant / award(deriv) | 17,000 | — | +$0 |
| 2023-03-28 | Thramann Jeffrey John | Executive Chairman | J Other acquisition | 1 | $1000.00 | −$1.0K |
| 2023-02-21 | Thramann Jeffrey John | Executive Chairman | P Open-market purchase | 1 | $1000.00 | +$1.0K |
| 2022-12-29 | Wesemann William | Director | A Grant / award(deriv) | 63,000 | — | +$0 |
| 2022-12-29 | Lorbiecki John Paul | Chief Financial Officer | P Open-market purchase | 18,304 | $0.45 | +$8.2K |
| 2022-12-29 | Lorbiecki John Paul | Chief Financial Officer | P Open-market purchase | 4,100 | $0.43 | +$1.8K |
| 2022-12-29 | Ness Brent | Chief Executive Officer | P Open-market purchase | 7,711 | $0.58 | +$4.5K |
| 2022-12-29 | Ness Brent | Chief Executive Officer | P Open-market purchase | 8,500 | $0.51 | +$4.3K |
| 2022-12-29 | Ness Brent | Chief Executive Officer | P Open-market purchase | 2,289 | $0.42 | +$961 |
| 2022-12-06 | Neal David K | Director | J Other acquisition | 152,128 | — | +$0 |
| 2022-12-06 | SC Capital 1 LLC | Former 10% Owner | J Other acquisition | 1,091,894 | — | +$0 |
| 2022-09-15 | Lorbiecki John Paul | Chief Financial Officer | A Grant / award(deriv) | 16,455 | — | +$0 |
| 2022-09-15 | Ness Brent | Chief Executive Officer | A Grant / award(deriv) | 75,582 | — | +$0 |
| 2022-09-15 | Thramann Jeffrey John | Executive Chairman | A Grant / award(deriv) | 185,285 | — | +$0 |
| 2022-04-25 | Neal David K | Director | P Open-market purchase(deriv) | 34,400 | — | +$0 |
| 2022-04-25 | Neal David K | Director | P Open-market purchase | 34,400 | $4.35 | +$149.6K |
| 2022-04-25 | Ness Brent | Chief Executive Officer | P Open-market purchase(deriv) | 1,000 | — | +$0 |
| 2022-04-25 | Ness Brent | Chief Executive Officer | P Open-market purchase | 1,000 | $4.35 | +$4.3K |
| 2022-04-25 | Wesemann William | Director | P Open-market purchase(deriv) | 11,000 | — | +$0 |
| 2022-04-25 | Wesemann William | Director | P Open-market purchase | 11,000 | $4.35 | +$47.8K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -1.55 | -1.34 | +13.55% |
| 2026-03-18 | -3.60 | -4.52 | -25.55% |
| 2025-11-12 | -2.64 | -2.93 | -10.98% |
| 2025-08-14 | -2.26 | -2.75 | -21.63% |
| 2025-04-09 | -1356.74 | -1628.09 | -20.00% |
| 2024-11-14 | -1628.09 | -1356.74 | +16.67% |
| 2024-08-14 | -2080.33 | -1356.74 | +34.78% |
| 2024-05-15 | -5155.61 | -3979.77 | +22.81% |
| 2023-11-14 | -13024.70 | -17366.27 | -33.33% |
| 2023-08-25 | -13024.70 | -26049.40 | -100.00% |
| 2023-07-03 | -14471.89 | -21707.84 | -50.00% |
| 2023-02-27 | -23155.03 | -14471.89 | +37.50% |
| 2022-11-14 | -17366.27 | -30390.97 | -75.00% |
| 2022-08-15 | -15919.08 | -70912.27 | -345.45% |